Merck (NYSE: MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

The Delaware Supreme Court reportedly ruled in favor of Bayer AG BAYRY BAYZF, stating that the company is not accountable for lawsuits associated with talc-based foot powder products obtained from ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware Apr. 29, 2025 6:45 AM ET Merck & Co., Inc. (MRK) ...

Merck said last week its biggest tariff exposure is through Keytruda and it has enough U.S. inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

Merck is seeking confirmation that Bayer is liable for talc claims that have been filed against both companies since 2014 when Bayer bought product lines from Merck in a $14 billion deal. The ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Akirastock By Brian Kaberline – Editor, Kansas City Business Journal Jun 29, 2020 Updated Jun 29, 2020 2:24pm CDT ...

Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as ...